F11 Antibody (Center) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P03951 |
---|---|
Clone Names | 80513119 |
Gene ID | 2160 |
---|---|
Other Names | Coagulation factor XI, FXI, Plasma thromboplastin antecedent, PTA, Coagulation factor XIa heavy chain, Coagulation factor XIa light chain, F11 |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | F11 |
---|---|
Function | Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX. |
Cellular Location | Secreted. |
Tissue Location | Isoform 2 is produced by platelets and megakaryocytes but absent from other blood cells |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This gene encodes coagulation factor XI of the bloodcoagulation cascade. This protein is present in plasma as azymogen, which is a unique plasma coagulation enzyme because itexists as a homodimer consisting of two identical polypeptidechains linked by disulfide bonds. During activation of the plasmafactor XI, an internal peptide bond is cleaved by factor XIIa (orXII) in each of the two chains, resulting in activated factor XIa,a serine protease composed of two heavy and two light chains heldtogether by disulfide bonds. This activated plasma factor XItriggers the middle phase of the intrisic pathway of bloodcoagulation by activating factor IX. Defects in this factor lead toRosenthal syndrome, a blood coagulation abnormality. [provided byRefSeq].
References
Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)Wong, P.C., et al. Thromb. Haemost. 104(2):302-310(2010)Whelihan, M.F., et al. J. Thromb. Haemost. 8(7):1532-1539(2010)Delluc, A., et al. Thromb. Haemost. 103(6):1161-1169(2010)Barber, M.J., et al. PLoS ONE 5 (3), E9763 (2010) :
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.